Subcutaneous Immunoglobulin (SCIG) from CSL Behring.
Hizentra is a 20% subcutaneous immunoglobulin product from CSL Behring — one of the most widely used SCIG products in the U.S. Its high concentration allows smaller infusion volumes, and its room-temperature storage simplifies travel and daily life.
Hizentra is FDA-approved for the following indications:
Hizentra is administered subcutaneously, typically weekly, via self-infusion at home using a small portable pump. Patients are trained on the technique by an infusion nurse and can administer doses independently within a few sessions. Some patients dose every two weeks once stable. The route allows more stable IgG levels and avoids the systemic side effects sometimes seen with IVIG.
The manufacturer offers a patient support program — CSL Behring IgIQ Patient Support — that can help with insurance navigation, copay assistance for eligible patients, nursing support, and ongoing education. More information is available at https://www.igiq.com.
Treatment with Hizentra is initiated and monitored by Dr. McNeil. Prior authorizations are handled in-house — patients are not asked to navigate insurance approvals on their own. Administration logistics are coordinated by the office team based on the route of therapy and patient preference.
Important safety note: This page is not a substitute for the FDA prescribing information. Risks, contraindications, drug interactions, and required monitoring vary by patient. The official manufacturer website (https://www.hizentra.com) provides the most current full prescribing and safety information. Treatment decisions and monitoring are individualized — please discuss with Dr. McNeil whether Hizentra is appropriate for your situation.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes only and is not medical advice. If you have an emergency, call 911.